Department of Pathology, The Southern Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
Department of Nephrology, Xijing Hospital, Air Force Medical University, Xi'an, Shaanxi 710000, P.R. China.
Int J Mol Med. 2021 Sep;48(3). doi: 10.3892/ijmm.2021.5002. Epub 2021 Jul 19.
Acute renal injury (ARI) is a life‑threatening condition and a main contributor to end‑stage renal disease, which is mainly caused by ischemia‑reperfusion (I/R). miR‑106b‑5p is a kidney function‑related miRNA; however, whether miR‑106b‑5p regulates the progression of ARI remains unclear. The present study thus aimed to examine the effects of miR‑106b‑5p antagonist on the regulation of ARI progression. It was found that miR‑106b‑5p expression was upregulated in the renal tissue of rats with I/R‑induced ARI and in NRK‑52E rat renal proximal tubular epithelial cells subjected to hypoxia‑reoxygenation (H/R). , H/R induction suppressed the proliferation, and promoted the apoptosis and autophagy of NRK‑52E cells, whereas miR‑106b‑5p antagonist (inhibition of miR‑106b‑5p) promoted the proliferation, and attenuated the apoptosis and autophagy of NRK‑52E cells under the H/R condition. Dual luciferase reporter gene assay validated that transcription factor 4 (TCF4) was a target of miR‑106b‑5p. It was further found that TCF4 overexpression promoted the proliferation, and inhibited the apoptosis and autophagy of NRK‑52E cells subjected to H/R. Moreover, the effects of miR‑106b‑5p antagonist on NRK‑52E cell proliferation, apoptosis and autophagy were mediated through the regulation of TCF4. , miR‑106b‑5p antagonist reduced the severity of renal injury, decreased cell proliferation in renal tissues and lowered the serum creatinine (Scr) and blood urea nitrogen (BUN) levels in the blood samples from rats with I/R‑induced ARI. On the whole, the findings presented herein demonstrate that miR‑106b‑5p antagonist attenuates ARI by promoting the proliferation, and suppressing the apoptosis and autophagy of renal cells via upregulating TCF4.
急性肾损伤 (ARI) 是一种危及生命的病症,也是导致终末期肾病的主要原因,其主要由缺血再灌注 (I/R) 引起。miR-106b-5p 是一种与肾功能相关的 miRNA;然而,miR-106b-5p 是否调节 ARI 的进展尚不清楚。因此,本研究旨在研究 miR-106b-5p 拮抗剂对调节 ARI 进展的影响。研究发现,I/R 诱导的 ARI 大鼠肾脏组织和缺氧再复氧 (H/R) 处理的 NRK-52E 大鼠肾近端肾小管上皮细胞中 miR-106b-5p 的表达上调。, H/R 诱导抑制 NRK-52E 细胞的增殖,促进其凋亡和自噬,而 miR-106b-5p 拮抗剂 (抑制 miR-106b-5p) 则促进 H/R 条件下 NRK-52E 细胞的增殖,减轻其凋亡和自噬。双荧光素酶报告基因检测验证转录因子 4 (TCF4) 是 miR-106b-5p 的靶基因。进一步研究发现,TCF4 过表达促进 H/R 处理的 NRK-52E 细胞的增殖,抑制其凋亡和自噬。此外,miR-106b-5p 拮抗剂对 NRK-52E 细胞增殖、凋亡和自噬的影响是通过调节 TCF4 介导的。, miR-106b-5p 拮抗剂减轻肾损伤的严重程度,减少肾组织中的细胞增殖,并降低 I/R 诱导的 ARI 大鼠血液样本中的血清肌酐 (Scr) 和血尿素氮 (BUN) 水平。总的来说,本研究结果表明,miR-106b-5p 拮抗剂通过上调 TCF4 促进肾细胞增殖,抑制细胞凋亡和自噬,从而减轻 ARI。